INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Centralized Monitoring: Exploring the Considerations and Challenges of Implementation

Rohit Gupta, MSc

Rohit Gupta, MSc

Associate Director - Risk Based Quality Management

Author picture
Discover how Centralized Monitoring (CM) is transforming clinical trials, boosting quality, safety, and efficiency through real-time data oversight. Indero’s Rohit Gupta, contributed to PHUSE's white paper, “Centralized Monitoring: Exploring the Considerations and Challenges of Implementation”. Key Takeaways: 1. Detect risks early, reduce site visits, cut costs; 2. Tailor CM to study needs and tech maturity; 3. Build CM skills and drive adoption. Why It Matters: CM is essential for modern, complex trials. This paper offers a roadmap for smarter, faster, and compliant monitoring.

Reinforce your centralized monitoring knowledge and expertise by downloading the full white paper now!

Contact form on home page

Common Questions About Centralized Monitoring

Explore the basics of centralized clinical monitoring, including key definitions and challenges, in this FAQ. Get more details in the full white paper.

What is centralized monitoring in clinical trials?

Centralized monitoring is a risk-based approach that uses remote, near real-time review of aggregated clinical and operational data to identify trends, outliers, and potential risks across sites and participants. Rather than focusing on individual data points through routine on-site visits, centralized monitoring enables earlier detection of issues related to data integrity, protocol compliance, and patient safety.

By continuously analyzing Key Risk Indicators (KRIs), Quality Tolerance Limits (QTLs), and statistical signals across the study, centralized monitoring helps identify emerging risks earlier than traditional methods. This early visibility allows teams to address issues such as:
  • Unusually low or high protocol deviation (PD) reporting rates
  • Unexpectedly low adverse event (AE) incidence rates
  • Abnormally low variability in assessment or endpoint scores
  • Inconsistencies in the number of raters assigned to critical endpoint assessments
  • High query rates indicating potential data quality or process issues
By identifying these challenges before they escalate, teams can protect trial participants while strengthening the reliability and credibility of the data used for decision-making and regulatory submissions.
Organizations often face challenges related to:
  • Inconsistent definitions of centralized monitoring
  • Data access limitations
  • Technology readiness
  • Skills gaps within study teams
  • Change management
Without clear education and cross-functional alignment, centralized monitoring can be misunderstood as redundant or as a replacement for on-site monitoring rather than a complementary, risk-focused enhancement to trial oversight. Our white paper outlines solutions to address these concerns.
Regulatory-ready documentation should clearly demonstrate when centralized monitoring reviews occurred, who conducted them, what data were reviewed, what risks or issues were identified, and what actions were taken in response. Periodic centralized monitoring reports play a critical role in showing adherence to the monitoring plan, traceability from signal detection to mitigation, and compliance with regulatory expectations outlined in risk-based monitoring guidance.
A common misconception is that centralized monitoring replaces on-site monitoring or simply adds unnecessary workload. In reality, it complements traditional monitoring by prioritizing critical data and directing on-site efforts more effectively. Others underestimate the value of trend analysis over time or assume advanced technology alone is sufficient, overlooking the importance of experienced personnel, cross-functional collaboration, and thoughtful implementation.
Talk to us

Jeff Smith

Chef de la direction
Linkedin

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >